Immix Biopharma (IMMX) announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18 clinical trial sites in its national footprint. “We are thrilled to report that NEXICART-2 is progressing faster than we expected. Responding to the unmet need across the country, we are expanding the NEXICART-2 clinical trial footprint to deliver cell therapy to this underserved population, where no FDA drugs are approved today,” said Ilya Rachman, CEO.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma Holds Annual Meeting, Elects Directors
- Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
- Immix Biopharma files $13.45M common stock ATM offering
- Immix Biopharma Enters At The Market Offering Agreement
- Immix Biopharma announces NXC-201 trial met primary endpoint